All stock lists
Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
Healthcare · Biotechnology
64.81+0.28 (+0.43%)
Insider Score
––Not scored
EXEL Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
EXEL Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 628.69 M | 610.81 M | 598.66 M | 597.75 M | 568.26 M |
| Revenue Growth (YoY) | 10.63 % | — | — | — | — |
| Cost of Revenue | 20.66 M | 19.95 M | 26.48 M | 18.57 M | 19.47 M |
| Gross Profit | 608.03 M | 590.86 M | 572.18 M | 579.18 M | 548.79 M |
| SG&A Expense | 147.63 M | 139.60 M | 123.02 M | 123.66 M | 134.86 M |
| R&D Expense | 211.99 M | 199.92 M | 213.25 M | 199.16 M | 200.36 M |
| Operating Expenses | 359.62 M | 339.52 M | 336.27 M | 322.82 M | 335.21 M |
| Operating Income | 248.41 M | 251.34 M | 235.91 M | 256.36 M | 213.58 M |
| Pretax Income | 262.68 M | 267.69 M | 252.69 M | 252.41 M | 230.41 M |
| Tax Provision | 50.63 M | 57.22 M | 8.16 M | 58.84 M | 45.57 M |
| Net Income | 212.05 M | 210.47 M | 244.53 M | 193.58 M | 184.85 M |
| EPS (Basic) | 0.85 | 0.81 | 0.92 | 0.72 | 0.68 |
| EPS (Diluted) | 0.82 | 0.79 | 0.88 | 0.69 | 0.65 |
| Shares Outstanding | 250.81 M | 258.33 M | 266.46 M | 268.42 M | 272.58 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.